Compare Travere Therapeutics Inc. Common Stock (TVTX) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while State Street Real Estate Select Sector SPDR ETF trades at $41.83 (market cap $7.83B). The key difference: State Street Real Estate Select Sector SPDR ETF is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, State Street Real Estate Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and State Street Real Estate Select Sector SPDR ETF for 77 Days on average.
| TVTX | XLRE | |
|---|---|---|
Market Cap | $4.88B | $7.83B |
Volume | 1,668,577 | 5,853,296 |
Sector | Health | Sector/Thematic |
52-Week High | $67.52 | $46.01 |
52-Week Low | $26.79 | $40.01 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $5.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XLRE, the State Street Real Estate Select Sector SPDR ETF, trades at $41.83, down 0.21% on the day. The technical outlook is mixed, with a bullish overall signal but bearish moving averages. Key financial ratios are not available in the provided data. Recent news highlights the fund's low expense ratio of 0.08% and its focus on 30 U.S. large-cap real estate holdings, positioning it as a cost-effective domestic real estate exposure tool.
The outlook for XLRE is influenced by competing factors: its low-cost structure is a strength, but the sector faces headwinds from rising bond yields and potential interest rate volatility. Investment opportunity lies in its role as a pure-play U.S. real estate ETF, while risks include macroeconomic sensitivity and competition from more diversified or thematic real estate funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
